Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Invivyd, Inc. - Common Stock (NQ: IVVD ) 0.9055 +0.0155 (+1.74%) Streaming Delayed Price Updated: 1:37 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Invivyd, Inc. - Common Stock < Previous 1 2 3 4 5 6 7 Next > This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday October 30, 2024 Via Benzinga Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability October 29, 2024 From Invivyd Via GlobeNewswire Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants October 29, 2024 From Invivyd Via GlobeNewswire Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 October 16, 2024 From Invivyd Via GlobeNewswire IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024 May 09, 2024 IVVD stock results show that Invivyd met analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data October 01, 2024 From Invivyd Via GlobeNewswire Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) September 23, 2024 From Invivyd Via GlobeNewswire Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 September 12, 2024 From Invivyd Via GlobeNewswire Invivyd to Participate in Upcoming Investor Conferences September 05, 2024 From Invivyd Via GlobeNewswire Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ September 04, 2024 From Invivyd Via GlobeNewswire Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest September 03, 2024 From Invivyd Via GlobeNewswire Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial August 27, 2024 From Invivyd Via GlobeNewswire Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket August 21, 2024 Via Benzinga IVVD Stock Earnings: Invivyd Misses EPS, Misses Revenue for Q2 2024 August 14, 2024 IVVD stock results show that Invivyd missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 14, 2024 From Invivyd Via GlobeNewswire Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights August 12, 2024 From Invivyd Via GlobeNewswire Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes July 01, 2024 From Invivyd Via GlobeNewswire Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants June 14, 2024 From Invivyd Via GlobeNewswire Invivyd to Participate at the Jefferies Global Healthcare Conference June 03, 2024 From Invivyd Via GlobeNewswire Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial May 31, 2024 From Invivyd Via GlobeNewswire Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer May 31, 2024 From Invivyd Via GlobeNewswire Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) May 29, 2024 From Invivyd Via GlobeNewswire Invivyd Elects Two New Independent Members to its Board of Directors May 22, 2024 From Invivyd Via GlobeNewswire Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference May 13, 2024 From Invivyd Via GlobeNewswire Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From Invivyd Via GlobeNewswire Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback May 07, 2024 From Invivyd Via GlobeNewswire Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights May 02, 2024 From Invivyd Via GlobeNewswire Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position April 30, 2024 From Invivyd Via GlobeNewswire Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™ April 15, 2024 From Invivyd Via GlobeNewswire Invivyd Announces CEO Transition April 12, 2024 Jeremy Gowler appointed Interim CEO From Invivyd Via GlobeNewswire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
